Stock Analysis

September 2024's UK Stock Picks For Possible Value Investing

LSE:SGE
Source: Shutterstock

The United Kingdom's stock market has been facing headwinds, with the FTSE 100 index closing lower due to weak trade data from China and a faltering global economy. Despite these challenges, value investing remains a viable strategy for discerning investors seeking opportunities in undervalued stocks.

Top 10 Undervalued Stocks Based On Cash Flows In The United Kingdom

NameCurrent PriceFair Value (Est)Discount (Est)
Gaming Realms (AIM:GMR)£0.401£0.7647.2%
GlobalData (AIM:DATA)£2.06£3.7244.6%
Tracsis (AIM:TRCS)£5.50£10.0145%
Ferrexpo (LSE:FXPO)£0.479£0.9449.3%
Informa (LSE:INF)£8.398£16.2348.3%
Redcentric (AIM:RCN)£1.2975£2.4346.7%
SysGroup (AIM:SYS)£0.34£0.6547.9%
Foxtons Group (LSE:FOXT)£0.622£1.1847.3%
Hochschild Mining (LSE:HOC)£1.872£3.5046.5%
BATM Advanced Communications (LSE:BVC)£0.20£0.3644.9%

Click here to see the full list of 61 stocks from our Undervalued UK Stocks Based On Cash Flows screener.

Let's explore several standout options from the results in the screener.

ConvaTec Group (LSE:CTEC)

Overview: ConvaTec Group PLC develops, manufactures, and sells medical products, services, and technologies across Europe, North America, and internationally with a market cap of £4.71 billion.

Operations: The company's revenue from the development, manufacture, and sale of medical products and technologies amounts to $2.20 billion.

Estimated Discount To Fair Value: 39.5%

ConvaTec Group appears undervalued based on its discounted cash flow (DCF) analysis, trading at £2.3 against an estimated fair value of £3.8. The company recently reported a significant increase in net income to US$78.6 million for H1 2024, up from US$55.7 million a year ago, alongside earnings per share growth from US$0.027 to US$0.038. Despite high debt levels, ConvaTec's earnings are forecasted to grow annually by 21%, outpacing the UK market average of 14.4%.

LSE:CTEC Discounted Cash Flow as at Sep 2024
LSE:CTEC Discounted Cash Flow as at Sep 2024

Sage Group (LSE:SGE)

Overview: The Sage Group plc, with a market cap of £10.34 billion, provides technology solutions and services for small and medium businesses in the United States, the United Kingdom, France, and internationally.

Operations: The company's revenue segments include £595 million from Europe, £1.01 billion from North America, and £488 million from the United Kingdom & Ireland.

Estimated Discount To Fair Value: 21.1%

Sage Group is trading at £10.37, significantly below its estimated fair value of £13.14, indicating it may be undervalued based on discounted cash flow analysis. The company reported a 9% revenue increase to £585 million for Q3 2024, driven by growth in the Sage Business Cloud portfolio. Despite high debt levels and insider selling, earnings are forecast to grow at 15.1% annually, outpacing the UK market's average growth rate of 14.4%.

LSE:SGE Discounted Cash Flow as at Sep 2024
LSE:SGE Discounted Cash Flow as at Sep 2024

Smith & Nephew (LSE:SN.)

Overview: Smith & Nephew plc, with a market cap of £10.16 billion, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally.

Operations: The company's revenue is segmented into Orthopaedics ($2.26 billion), Sports Medicine & ENT ($1.77 billion), and Advanced Wound Management (AWM) ($1.61 billion).

Estimated Discount To Fair Value: 35%

Smith & Nephew is trading at £11.65, well below its estimated fair value of £17.92, suggesting it is undervalued based on discounted cash flow analysis. The company reported H1 2024 sales of $2.83 billion and net income of $214 million, reflecting solid financial performance despite high debt levels. Recent strategic moves include a three-year distribution agreement with InfuSystem Holdings and the appointment of Angie Risley as Senior Independent Director, both potentially enhancing future cash flows and operational efficiency.

LSE:SN. Discounted Cash Flow as at Sep 2024
LSE:SN. Discounted Cash Flow as at Sep 2024

Where To Now?

Interested In Other Possibilities?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com